2025
SJR Q1
JCR Q1 · 6,1
21 matched articles
SCIE
Journal detail
Current Neuropharmacology
- Publisher
- Bentham Science Publishers
- Country
- United Arab Emirates · Middle East
- Type
- journal
- ISSN
-
1570159X18756190
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,642
- Quartile Q1
- H-Index 125
- Cites/doc 6,36
- Docs (3y) 481
- Cites (3y) 3.318
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 6,1
- 5Y JIF 7,7
- JCI 0,89
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Medicine (miscellaneous) Q1
- Neurology Q1
- Neurology (clinical) Q1
- Pharmacology Q1
- Pharmacology (medical) Q1
- Psychiatry and Mental Health Q1
Areas
- Medicine
- Neuroscience
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Neurosciences | Pharmacology & Pharmacy
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,642 | 6,1 | 7,7 | 0,89 | Q2 | 125 |
| 2024 | Q1 | Q1 | 1,555 | 5,3 | 7,4 | 0,86 | Q2 | 112 |
| 2023 | Q1 | Q1 | 1,299 | 4,8 | 7,1 | 0,84 | Q2 | 112 |
| 2022 | Q1 | Q1 | 1,168 | 5,3 | 7,9 | 0,82 | Q2 | 112 |
| 2021 | Q1 | Q1 | 1,722 | 7,7 | 9,6 | 0,97 | Q2 | 112 |
| 2020 | Q1 | Q1 | 1,955 | 7,4 | 8,3 | 0,93 | Q2 | 112 |
| 2019 | Q1 | Q1 | 1,531 | 4,7 | 5,5 | 1 | Q2 | 112 |
| 2018 | — | Q1 | — | 4,6 | 5,7 | 1,09 | Q1 | — |
| 2017 | Q1 | Q1 | 1,21 | 4,1 | 5,1 | 1,13 | Q1 | 112 |
| 2016 | Q1 | Q2 | 1,385 | 3,4 | 3,6 | — | — | 112 |
| 2015 | Q1 | Q1 | 1,392 | 3,8 | 3,5 | — | — | 112 |
| 2014 | Q1 | Q2 | 1,212 | 3 | 3,8 | — | — | 112 |
| 2013 | Q1 | Q2 | 0,951 | 2,3 | 3,9 | — | — | 112 |
| 2012 | Q2 | Q3 | 0,799 | 2 | 3,1 | — | — | 112 |
| 2011 | Q1 | Q2 | 1,309 | 2,8 | 3,4 | — | — | 112 |
| 2010 | Q1 | Q2 | 1,271 | 2,8 | 3 | — | — | 112 |
| 2009 | — | Q3 | — | 1,7 | 1,7 | — | — | — |
| 2008 | — | Q4 | — | 1,2 | 1,1 | — | — | — |
| 2007 | — | Q4 | — | 0,8 | 1,2 | — | — | — |
| 2006 | — | Q4 | — | 1 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | NEUROSCIENCES | SCIE | Q1 | Q2 | 49/330 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 43/356 |
| 2024 | NEUROSCIENCES | SCIE | Q1 | Q2 | 46/314 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 42/352 |
| 2023 | NEUROSCIENCES | SCIE | Q1 | Q2 | 57/310 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 50/354 |
| 2022 | NEUROSCIENCES | SCIE | Q1 | Q2 | 62/272 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 54/278 |
| 2021 | NEUROSCIENCES | SCIE | Q1 | Q2 | 35/275 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 24/279 |
| 2020 | NEUROSCIENCES | SCIE | Q1 | Q2 | 35/273 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 18/276 |
| 2019 | NEUROSCIENCES | SCIE | Q1 | Q2 | 61/272 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q2 | 38/271 |
| 2018 | NEUROSCIENCES | SCIE | Q1 | Q2 | 59/267 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 33/267 |
| 2017 | NEUROSCIENCES | SCIE | Q2 | Q2 | 69/261 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 40/261 |
| 2016 | NEUROSCIENCES | SCIE | Q2 | — | 94/259 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 66/257 |
| 2015 | NEUROSCIENCES | SCIE | Q2 | — | 72/256 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 55/255 |
| 2014 | NEUROSCIENCES | SCIE | Q2 | — | 114/252 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 75/255 |
| 2013 | NEUROSCIENCES | SCIE | Q3 | — | 160/252 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 121/256 |
| 2012 | NEUROSCIENCES | SCIE | Q3 | — | 176/252 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 149/261 |
| 2011 | NEUROSCIENCES | SCIE | Q2 | — | 117/244 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 90/261 |
| 2010 | NEUROSCIENCES | SCIE | Q3 | — | 120/239 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 86/252 |
| 2009 | NEUROSCIENCES | SCIE | Q4 | — | 175/231 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 155/237 |
| 2008 | NEUROSCIENCES | SCIE | Q4 | — | 185/221 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 171/219 |
| 2007 | NEUROSCIENCES | SCIE | Q4 | — | 189/211 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 174/205 |
| 2006 | NEUROSCIENCES | SCIE | Q4 | — | 172/200 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 158/199 |